Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES F LOVELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174629448
CMS profile
325880
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$681.28

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $681.28 22

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES F LOVELL

NPI 1174629448 · CMS profile ID 325880

Allopathic & Osteopathic Physicians / Internal Medicine

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174629448?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174629448?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174629448?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1174629448?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $681.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $13.5112/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207147057 CMS
Novartis Pharmaceuticals Corporation $22.3611/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597657 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.0511/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222803371 CMS
AstraZeneca Pharmaceuticals LP $124.9410/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206918244 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.2810/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222803369 CMS
Corcept Therapeutics $23.2010/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214174160 CMS
Corcept Therapeutics $24.2009/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214174154 CMS
AstraZeneca Pharmaceuticals LP $21.0708/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207050359 CMS
Corcept Therapeutics $121.8707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214174164 CMS
Corcept Therapeutics $23.9407/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214174082 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4807/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222803367 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.8506/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222803365 CMS
Corcept Therapeutics $12.9906/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214174080 CMS
Corcept Therapeutics $26.3406/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214174078 CMS
AstraZeneca Pharmaceuticals LP $24.7805/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206639947 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.7304/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222803363 CMS
Lilly USA, LLC $21.6104/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186555744 CMS
Novartis Pharmaceuticals Corporation $16.7404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597639 CMS
AstraZeneca Pharmaceuticals LP $22.1104/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206499190 CMS
Lilly USA, LLC $19.6703/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186490643 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.1401/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222803361 CMS
AstraZeneca Pharmaceuticals LP $35.4201/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206208912 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,516.90 64
PY2020 $2,823.11 39
PY2021 $2,590.74 45
PY2022 $737.64 35
PY2023 $454.03 20
PY2024 $2,529.63 39
PY2025 $681.28 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,318.22 41
PY2024 Principal investigator $226,779.68 27
PY2023 Principal investigator $241,422.11 79
PY2022 Principal investigator $283,192.02 266
PY2021 Principal investigator $197,651.91 425
PY2020 Principal investigator $248,697.42 325
PY2019 Recipient $12,988.10 1
PY2019 Principal investigator $359,002.06 260

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

325 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $990.00 12/25/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
(GOULD): a Registry of High Cardiovascular Risk Subjects in the United States No dispute reported 06/30/2026 731634875
Principal investigator 1 Novo Nordisk AS $1,534.78 12/22/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334323
Principal investigator 1 Novo Nordisk AS $3,969.00 12/22/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334329
Principal investigator 1 Novo Nordisk AS $200.00 12/22/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334331
Principal investigator 1 Novo Nordisk AS $41.00 12/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 822169669
Principal investigator 1 Novo Nordisk AS $41.00 12/18/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 822169665
Principal investigator 1 Novo Nordisk AS $50.00 12/18/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 822171049
Principal investigator 1 Novo Nordisk AS $82.00 12/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 822169667
Principal investigator 1 Novo Nordisk AS $400.00 12/10/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334327
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770191
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770193
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770195
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770807
Principal investigator 1 Merck Sharp & Dohme Corporation $3.30 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770809
Principal investigator 1 Merck Sharp & Dohme Corporation $7.10 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770811
Principal investigator 1 Merck Sharp & Dohme Corporation $0.70 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770813
Principal investigator 1 Merck Sharp & Dohme Corporation $1.30 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770815
Principal investigator 1 Merck Sharp & Dohme Corporation $140.64 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770855
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770857
Principal investigator 1 Merck Sharp & Dohme Corporation $27.50 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770859
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770861
Principal investigator 1 Merck Sharp & Dohme Corporation $33.60 12/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770863
Principal investigator 1 Novo Nordisk AS $5,940.54 11/30/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334325
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 11/25/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older No dispute reported 06/30/2026 740770805
Principal investigator 1 Novo Nordisk AS $1,827.02 11/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334321
Principal investigator 1 Novo Nordisk AS $2,268.01 10/29/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334309
Principal investigator 1 Novo Nordisk AS $1,816.56 10/29/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334317
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334117
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334119
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334121
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334123
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334125
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334127
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334129
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334131
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334133
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334135
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334137
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334139
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334141
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334143
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334145
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334147
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334149
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334151
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334153
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334155
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334157
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334159
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334161
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334163
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334165
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334167
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334169
Principal investigator 1 Novo Nordisk AS $12.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334171
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334173
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334175
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334177
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334179
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334181
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334183
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334185
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334187
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334189
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334191
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334193
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334195
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334197
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334199
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334201
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334203
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334205
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334207
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334209
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334211
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334213
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334215
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334217
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334219
Principal investigator 1 Novo Nordisk AS $28.45 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334221
Principal investigator 1 Novo Nordisk AS $65.34 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334223
Principal investigator 1 Novo Nordisk AS $138.85 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334225
Principal investigator 1 Novo Nordisk AS $15.60 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334227
Principal investigator 1 Novo Nordisk AS $44.97 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334229
Principal investigator 1 Novo Nordisk AS $23.70 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334231
Principal investigator 1 Novo Nordisk AS $10.98 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334233
Principal investigator 1 Novo Nordisk AS $108.00 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334235
Principal investigator 1 Novo Nordisk AS $45.75 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334237
Principal investigator 1 Novo Nordisk AS $51.92 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334239
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334241
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334243
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334245
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334247
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334249
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334251
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334253
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334255
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334257
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334259
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334261
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334263
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334265
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334267
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334269
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334271
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334273
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334275
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334277
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334279
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334281
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334283
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334285
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334287
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334289
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334291
Principal investigator 1 Novo Nordisk AS $16.25 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334293
Principal investigator 1 Novo Nordisk AS $36.00 10/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334295
Principal investigator 1 Amgen Inc. $925.00 10/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) No dispute reported 06/30/2026 731626265
Principal investigator 1 Novo Nordisk AS $23.06 10/06/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334319
Principal investigator 1 Novo Nordisk AS $4,998.24 09/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334313
Principal investigator 1 Novo Nordisk AS $200.00 09/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334315
Principal investigator 1 Merck Sharp & Dohme Corporation $5,452.20 09/23/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770767
Principal investigator 1 Novo Nordisk AS $5,455.72 09/22/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334307
Principal investigator 1 Amgen Inc. $3,478.00 09/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) No dispute reported 06/30/2026 731626261
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,712.82 09/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 721497853
Principal investigator 1 SANOFI US SERVICES INC. $3,867.45 09/02/2020 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744048543
Principal investigator 1 Novo Nordisk AS $3,147.66 08/27/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334311
Principal investigator 1 Novo Nordisk AS $9,649.12 08/25/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334303
Principal investigator 1 Novo Nordisk AS $995.62 08/25/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334305
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $21,126.75 08/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
EFC-14875 No dispute reported 06/30/2026 752054669
Principal investigator 1 Novo Nordisk AS $27.96 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334101
Principal investigator 1 Novo Nordisk AS $2.55 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334103
Principal investigator 1 Novo Nordisk AS $24.99 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334105
Principal investigator 1 Novo Nordisk AS $4.50 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334107
Principal investigator 1 Novo Nordisk AS $30.00 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334109
Principal investigator 1 Novo Nordisk AS $3.25 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334111
Principal investigator 1 Novo Nordisk AS $4.50 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334113
Principal investigator 1 Novo Nordisk AS $18.00 08/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334115
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,627.40 08/11/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEVELS AMONG PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 721497855
Principal investigator 1 Novo Nordisk AS $691.74 07/30/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334081
Principal investigator 1 Novo Nordisk AS $769.22 07/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334085
Principal investigator 1 Novo Nordisk AS $27.96 07/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334301
Principal investigator 1 Amgen Inc. $656.00 07/23/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) No dispute reported 06/30/2026 731626269
Principal investigator 1 Novo Nordisk AS $27.96 07/22/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334299
Principal investigator 1 Novo Nordisk AS $27.96 07/13/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334297
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770671
Principal investigator 1 Merck Sharp & Dohme Corporation $6.60 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770673
Principal investigator 1 Merck Sharp & Dohme Corporation $1.40 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770711
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770713
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770715
Principal investigator 1 Merck Sharp & Dohme Corporation $2.00 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770717
Principal investigator 1 Merck Sharp & Dohme Corporation $2.60 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770719
Principal investigator 1 Merck Sharp & Dohme Corporation $242.00 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770757
Principal investigator 1 Merck Sharp & Dohme Corporation $528.00 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770759
Principal investigator 1 Merck Sharp & Dohme Corporation $55.00 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770761
Principal investigator 1 Merck Sharp & Dohme Corporation $67.20 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770763
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 07/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770765
Principal investigator 1 Novo Nordisk AS $2,475.36 06/23/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334079
Principal investigator 1 Novo Nordisk AS $1,889.43 06/23/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334083
Principal investigator 1 Novo Nordisk AS $2.65 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334087
Principal investigator 1 Novo Nordisk AS $24.99 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334089
Principal investigator 1 Novo Nordisk AS $4.50 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334091
Principal investigator 1 Novo Nordisk AS $30.00 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334093
Principal investigator 1 Novo Nordisk AS $3.25 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334095
Principal investigator 1 Novo Nordisk AS $4.50 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334097
Principal investigator 1 Novo Nordisk AS $18.00 06/19/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334099
Principal investigator 1 Merck Sharp & Dohme Corporation $98.02 06/18/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726209
Principal investigator 1 SANOFI US SERVICES INC. $3,804.20 06/15/2020 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744048313
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770187
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770189
Principal investigator 1 Merck Sharp & Dohme Corporation $0.70 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770479
Principal investigator 1 Merck Sharp & Dohme Corporation $1.00 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770481
Principal investigator 1 Merck Sharp & Dohme Corporation $1.30 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770483
Principal investigator 1 Merck Sharp & Dohme Corporation $121.00 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770487
Principal investigator 1 Merck Sharp & Dohme Corporation $27.50 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770531
Principal investigator 1 Merck Sharp & Dohme Corporation $3.30 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770571
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770573
Principal investigator 1 Merck Sharp & Dohme Corporation $33.60 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770577
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770579
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770627
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770665
Principal investigator 1 Merck Sharp & Dohme Corporation $7.10 06/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770667
Principal investigator 1 Merck Sharp & Dohme Corporation $3,154.80 06/05/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770851
Principal investigator 1 Akcea Therapeutics, Inc. $11,285.75 05/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD No dispute reported 06/30/2026 750820851
Principal investigator 1 Novo Nordisk AS $5,032.26 05/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333901
Principal investigator 1 Novo Nordisk AS $200.00 05/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333903
Principal investigator 1 Novo Nordisk AS $2,507.07 05/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333911
Principal investigator 1 Amgen Inc. $1,488.00 05/20/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC - HF No dispute reported 06/30/2026 731633763
Principal investigator 1 Novo Nordisk AS $49.98 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334065
Principal investigator 1 Novo Nordisk AS $9.00 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334067
Principal investigator 1 Novo Nordisk AS $36.00 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334069
Principal investigator 1 Novo Nordisk AS $6.50 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334071
Principal investigator 1 Novo Nordisk AS $5.30 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334073
Principal investigator 1 Novo Nordisk AS $60.00 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334075
Principal investigator 1 Novo Nordisk AS $9.00 05/15/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334077
Principal investigator 1 Akcea Therapeutics, Inc. $9,870.20 05/14/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
SIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) No dispute reported 06/30/2026 750820767
Principal investigator 1 SANOFI US SERVICES INC. $5,201.45 05/11/2020 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744048289
Principal investigator 1 Novo Nordisk AS $4,219.56 04/30/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333899
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333917
Principal investigator 1 Novo Nordisk AS $885.38 04/23/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333909
Principal investigator 1 Merck Sharp & Dohme Corporation $3,242.40 04/17/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770849
Principal investigator 1 Merck Sharp & Dohme Corporation $8.25 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770181
Principal investigator 1 Merck Sharp & Dohme Corporation $84.00 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770183
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770185
Principal investigator 1 Merck Sharp & Dohme Corporation $1.75 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770485
Principal investigator 1 Merck Sharp & Dohme Corporation $2.50 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770525
Principal investigator 1 Merck Sharp & Dohme Corporation $21.30 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770527
Principal investigator 1 Merck Sharp & Dohme Corporation $23.75 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770529
Principal investigator 1 Merck Sharp & Dohme Corporation $3.25 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770533
Principal investigator 1 Merck Sharp & Dohme Corporation $302.50 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770575
Principal investigator 1 Merck Sharp & Dohme Corporation $660.00 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770619
Principal investigator 1 Merck Sharp & Dohme Corporation $68.75 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770621
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770623
Principal investigator 1 Merck Sharp & Dohme Corporation $17.00 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770625
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770669
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 04/08/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740770853
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333919
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333921
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333923
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333925
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333927
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333929
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333931
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333933
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333935
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333937
Principal investigator 1 Novo Nordisk AS $10.60 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333939
Principal investigator 1 Novo Nordisk AS $5.45 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333941
Principal investigator 1 Novo Nordisk AS $3.03 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333943
Principal investigator 1 Novo Nordisk AS $39.95 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333945
Principal investigator 1 Novo Nordisk AS $72.00 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333947
Principal investigator 1 Novo Nordisk AS $19.96 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333949
Principal investigator 1 Novo Nordisk AS $2.65 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333951
Principal investigator 1 Novo Nordisk AS $30.00 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333953
Principal investigator 1 Novo Nordisk AS $4.50 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333955
Principal investigator 1 Novo Nordisk AS $3.25 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333957
Principal investigator 1 Novo Nordisk AS $24.99 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333959
Principal investigator 1 Novo Nordisk AS $4.50 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333961
Principal investigator 1 Novo Nordisk AS $18.00 04/02/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333963
Principal investigator 1 Novo Nordisk AS $5,153.63 03/26/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333907
Principal investigator 1 Novo Nordisk AS $9,118.98 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333895
Principal investigator 1 Novo Nordisk AS $200.00 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333897
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333965
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333967
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333969
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333971
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333973
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333975
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333977
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333979
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333981
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333983
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333985
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333987
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333989
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333991
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333993
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333995
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333997
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333999
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334001
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334003
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334005
Principal investigator 1 Novo Nordisk AS $10.20 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334007
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334009
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334011
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334013
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334015
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334017
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334019
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334021
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334023
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334025
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334027
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334029
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334031
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334033
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334035
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334037
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334039
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334041
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334043
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334045
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334047
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334049
Principal investigator 1 Novo Nordisk AS $45.52 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334051
Principal investigator 1 Novo Nordisk AS $55.54 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334053
Principal investigator 1 Novo Nordisk AS $15.60 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334055
Principal investigator 1 Novo Nordisk AS $25.96 03/24/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334057
Principal investigator 1 Novo Nordisk AS $5,990.22 02/27/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333893
Principal investigator 1 Amgen Inc. $3,500.00 02/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
(GOULD): a Registry of High Cardiovascular Risk Subjects in the United States No dispute reported 06/30/2026 731634881
Principal investigator 1 Novo Nordisk AS $23.06 02/21/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333915
Principal investigator 1 SANOFI US SERVICES INC. $3,569.60 02/18/2020 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744048275
Principal investigator 1 Merck Sharp & Dohme Corporation $1,020.00 02/14/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726113
Principal investigator 1 Novo Nordisk AS $24.99 02/04/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333913
Principal investigator 1 SANOFI US SERVICES INC. $2,309.20 02/04/2020 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744048269
Principal investigator 1 Akcea Therapeutics, Inc. $4,670.00 01/30/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD No dispute reported 06/30/2026 750820285
Principal investigator 1 Amgen Inc. $10,384.00 01/30/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC - HF No dispute reported 06/30/2026 731633771
Principal investigator 1 Amgen Inc. $2,391.87 01/29/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC - HF No dispute reported 06/30/2026 731633767
Principal investigator 1 Novo Nordisk AS $5,387.04 01/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742333891
Principal investigator 1 Novo Nordisk AS $470.82 01/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742333905
Principal investigator 1 Novo Nordisk AS $23.06 01/28/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334063
Principal investigator 1 Novo Nordisk AS $23.06 01/23/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 742334061
Principal investigator 1 SANOFI US SERVICES INC. $4,318.00 01/21/2020 Non-covered Recipient Entity
York Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu No dispute reported 06/30/2026 744048249
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,042.06 01/16/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
Exercise capacity study in HFrEF No dispute reported 06/30/2026 751188815
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 01/14/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726247
Principal investigator 1 Novo Nordisk AS $24.99 01/10/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 742334059
Principal investigator 1 Amgen Inc. $318.37 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
GALACTIC - HF No dispute reported 06/30/2026 731633775
Principal investigator 1 Merck Sharp & Dohme Corporation $14.25 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740725565
Principal investigator 1 Merck Sharp & Dohme Corporation $17.00 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740725567
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726115
Principal investigator 1 Merck Sharp & Dohme Corporation $396.00 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726155
Principal investigator 1 Merck Sharp & Dohme Corporation $4.95 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726157
Principal investigator 1 Merck Sharp & Dohme Corporation $41.25 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726159
Principal investigator 1 Merck Sharp & Dohme Corporation $5.70 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726161
Principal investigator 1 Merck Sharp & Dohme Corporation $50.40 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726163
Principal investigator 1 Merck Sharp & Dohme Corporation $79.20 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726201
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726203
Principal investigator 1 Merck Sharp & Dohme Corporation $181.50 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726205
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726207
Principal investigator 1 Merck Sharp & Dohme Corporation $1.05 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726249
Principal investigator 1 Merck Sharp & Dohme Corporation $1.50 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726251
Principal investigator 1 Merck Sharp & Dohme Corporation $1.95 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726253
Principal investigator 1 Merck Sharp & Dohme Corporation $10.20 01/09/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740726255
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,212.96 01/06/2020 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
Exercise capacity study in HFpEF No dispute reported 06/30/2026 751188813